Literature DB >> 8424293

The effects of prophylactic dixyrazine on postoperative vomiting after two different anaesthetic methods for squint surgery in children.

E Karlsson1, L E Larsson, K Nilsson.   

Abstract

The incidence of postoperative vomiting after squint surgery was studied for two anaesthetic techniques with and without prophylactic dixyrazine. After induction, anaesthesia was maintained with either fentanyl/pancuronium/nitrous oxide or halothane/nitrous oxide in two randomly selected groups of 58 children each. Half of the children in each group were randomly allocated to receive dixyrazine 0.25 mg kg-1 i.v. after surgery had been completed but before reversal of muscle relaxants or termination of anaesthesia. With prophylactic dixyrazine the incidence of postoperative vomiting was significantly reduced from 69% (20/29) to 21% (6/29) in the fentanyl group and from 45% (13/29) to 10% (3/29) in the halothane group. Without prophylactic dixyrazine, 20 of 29 children in the fentanyl group vomited compared to 13 of 29 in the halothane group (n.s.). Thus, prophylactic dixyrazine reduced the incidence of vomiting in children given either opioid or halothane anaesthesia for squint surgery. In comparable groups avoidance of opioid anaesthetic technique and use of prophylactic dixyrazine resulted in a greatly reduced incidence of vomiting.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8424293     DOI: 10.1111/j.1399-6576.1993.tb03596.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  3 in total

Review 1.  Update on the management of postoperative nausea and vomiting.

Authors:  Anthony L Kovac
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

Review 2.  Management of postoperative nausea and vomiting in children.

Authors:  Anthony L Kovac
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

3.  Ketoprofen for add-on pain treatment to paracetamol after strabismus surgery in children.

Authors:  Hannu Kokki; Sinikka Purhonen; Markku Teräsvirta; Paula Ylönen
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.